C WorldWide Group Holding A S Decreases Position in Natera, Inc. (NASDAQ:NTRA)

C WorldWide Group Holding A S reduced its position in shares of Natera, Inc. (NASDAQ:NTRA) by 39.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 200,000 shares of the medical research company’s stock after selling 130,000 shares during the period. Natera comprises approximately 0.4% of C WorldWide Group Holding A S’s portfolio, making the stock its 27th largest position. C WorldWide Group Holding A S owned approximately 0.15% of Natera worth $31,660,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Chartwell Investment Partners LLC lifted its position in shares of Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the last quarter. Cerity Partners LLC lifted its position in shares of Natera by 27.0% during the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after purchasing an additional 18,316 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Natera during the 3rd quarter worth $385,000. Everence Capital Management Inc. purchased a new stake in shares of Natera during the 4th quarter worth $573,000. Finally, First Turn Management LLC purchased a new stake in shares of Natera during the 3rd quarter worth $19,760,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Price Performance

Shares of NASDAQ NTRA opened at $162.31 on Monday. The stock has a market cap of $21.43 billion, a price-to-earnings ratio of -92.22 and a beta of 1.66. Natera, Inc. has a 52 week low of $69.74 and a 52 week high of $183.00. The company’s 50-day moving average price is $167.98 and its 200 day moving average price is $145.85. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Insiders Place Their Bets

In other Natera news, insider John Fesko sold 669 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $159.60, for a total transaction of $106,772.40. Following the sale, the insider now directly owns 114,142 shares of the company’s stock, valued at $18,217,063.20. This trade represents a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 78,553 shares of the firm’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the sale, the chief executive officer now directly owns 267,629 shares in the company, valued at $44,150,756.13. This represents a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 295,772 shares of company stock valued at $49,741,699 in the last ninety days. Insiders own 7.60% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on NTRA shares. Morgan Stanley lifted their price objective on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. Piper Sandler lifted their price target on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. Sanford C. Bernstein raised their price target on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, January 10th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Finally, Canaccord Genuity Group increased their price target on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.94.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.